Feed: Amritsar CRWE Newswire - AggScore: 45.4

Delaware Chancery Court Issues Final Order And Judgment Upholding Its Favorable Ruling

---

Court Provides Clarity on Payment Process to PharmAthene ANNAPOLIS, Md., June 1, 2012 (CRWENewswire) — PharmAthene, Inc. (NYSE Amex: PIP) today announced that the Delaware Court of Chancery has issued its final judgment in the Company’s litigation against SIGA Technologies. Upholding its September 22, 2011 ruling, the Court awarded PharmAthene 50% of the net profits over [Read the Rest...]

Southern California Investment Forum Hosts an Investor Gathering Friday, June 1 at the Pacific Club in Newport Beach

---

LOS ANGELES, May 31, 2012 (CRWENEWSWIRE) — WallStreet Research™, a leading independent analyst research firm focusing on the small and micro-cap marketplace, announced that it will hold The Southern California Investment Forum (SCIF) Friday, June 1, 2012 at the Pacific Club in Newport Beach, CA. The event will present selected emerging companies to an [Read the Rest...]

BP Awards Emerson Multimillion-Dollar Contract To Provide Automation Technologies, Services For North Sea Oil Production

---

Integrated control and safety systems will help BP manage operations of two new platforms for the Clair Ridge project AUSTIN, Texas–(CRWENewswire)–BP has awarded Emerson Process Management, a global business of Emerson (NYSE:EMR), a $23 million contract to supply control and safety systems for two new offshore oil platforms in the North Sea. The platforms are part [Read the Rest...]

CytRx Announces the Publication of INNO-206 Findings in Multiple Myeloma in Clinical Cancer Research

---

Animal and in vitro studies show INNO-206 produced anti-multiple myeloma effects with less toxicity than doxorubicin Study conducted under the direction of Dr. James R. Berenson at the Institute for Myeloma & Bone Center Research LOS ANGELES–(CRWENewswire)–CytRx Corporation (Nasdaq:CYTR), a biopharmaceutical company specializing in oncology, today announced that in animal and in vitro studies, its tumor-targeting doxorubicin [Read the Rest...]

SunOpta Enters Into Agreement to Divest Its Canadian Based Natural Health Products Business

---

TORONTO, May 25, 2012 (CRWENewswire) — SunOpta Inc. (”SunOpta” or the “Company”) (Nasdaq:STKL) (TSX:SOY) today announced that it has signed a definitive agreement to sell its Canadian natural health products distribution business (operated as Purity Life Natural Health Products) to an affiliate of Banyan Capital Partners (”Banyan”). The transaction, valued at CDN $14,700,000, before transaction [Read the Rest...]

Apricus Biosciences Strengthens Vitaros(R) and Nexact(R) Patent Estate With Two New Patent Allowances

---

SAN DIEGO, May 25, 2012 (CRWENewswire) — Apricus Biosciences, Inc. (”Apricus Bio” or the “Company”) (Nasdaq:APRI) (http://www.apricusbio.com) announced today that the Canadian Intellectual Property Office issued a Notice of Allowance for a Canadian patent on certain methods of manufacture for the Company’s platform NexACT(R) drug delivery technology. Specifically, the patent covers the synthesis of Dodecyl 2-(N, [Read the Rest...]

Willbros Awarded Construction Contract for Hydrogen Pipeline

---

HOUSTON, May 22, 2012 (CRWENewswire) — Willbros Group, Inc. (NYSE:WG) announced today that a unit of its Oil & Gas segment has been awarded a contract by Praxair, Inc. to construct 52 miles of 12-inch pipeline. The hydrogen pipeline will originate at Praxair’s plant in Geismar, Louisiana and will terminate at Valero’s refinery in Norco, [Read the Rest...]

China Hydroelectric Corporation Receives New Tariff Increases for Power Projects in Yunnan and Fujian Provinces

---

- The Dazhaihe hydroelectric power project in Yunnan receives an effective tariff increase of 17% - Three more hydroelectric power projects in Fujian province receive tariff increases, the second such tariff increase in Fujian in recent months NEW YORK, May 21, 2012 (CRWENewswire) — China Hydroelectric Corporation (NYSE: CHC, CHCWS) (”China Hydroelectric” or the “Company”), an owner, [Read the Rest...]

PA32540 Provides Faster Gastric Acid Reduction Than Enteric-Coated Omeprazole (40 mg)

---

POZEN Presents Phase 1 Data at Digestive Disease Week 2012 SAN DIEGO–(CRWENewswire)–POZEN Inc. (NASDAQ:POZN), a pharmaceutical company committed to transforming medicine that transforms lives, presented data today from a Phase 1 study that found that the investigational compound, PA32540, provides faster protection compared with delayed-release, enteric-coated omeprazole (40 mg), as measured by mean time to gastric [Read the Rest...]

Perrigo Announces FDA Final Approval and Launch of Store Brand OTC Lansoprazole 15mg Capsules

---

ALLEGAN, Mich., May 18, 2012 (CRWENewswire) — Perrigo Company (Nasdaq:PRGO;TASE) today announced that it has received final approval from the U.S. Food and Drug Administration for its abbreviated new drug application (ANDA) for Lansoprazole capsules (15 mg). Shipments of product to customers have already begun. This new product for the U.S. store brand market is bioequivalent [Read the Rest...]